{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:29Z","timestamp":1787020529070,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1057-3","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T10:03:51Z","timestamp":1558519431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8074-1877","authenticated-orcid":false,"given":"C\u00e9dric","family":"Vonarburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Loetscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin O.","family":"Spycher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Kropf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Illi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Steinfuehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Koernig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Edler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Miescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"K\u00e4sermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian W.","family":"Zuercher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fimmu.2011.00054","volume":"2","author":"W Al-Herz","year":"2011","unstructured":"Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011;2:54.","journal-title":"Front Immunol"},{"issue":"5 Suppl 1","key":"1057_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","volume":"94","author":"FA Bonilla","year":"2005","unstructured":"Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1\u201363.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1057_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","volume":"28","author":"M Berger","year":"2008","unstructured":"Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28(2):413\u201337 x.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"6","key":"1057_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaip.2013.09.013","volume":"1","author":"M Kuruvilla","year":"2013","unstructured":"Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1(6):573\u201382.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl 1","key":"1057_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/cei.12516","volume":"178","author":"S Jolles","year":"2014","unstructured":"Jolles S. Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol. 2014;178(Suppl 1):67\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"1057_CR6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","volume":"119","author":"ES Resnick","year":"2012","unstructured":"Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650\u20137.","journal-title":"Blood."},{"issue":"1","key":"1057_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaci.2010.04.016","volume":"126","author":"L Kainulainen","year":"2010","unstructured":"Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2010;126(1):120\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1057_CR8","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.1111\/1469-0691.12193","volume":"19","author":"V Peltola","year":"2013","unstructured":"Peltola V, Waris M, Kainulainen L, Kero J, Ruuskanen O. Virus shedding after human rhinovirus infection in children, adults and patients with hypogammaglobulinaemia. Clin Microbiol Infect. 2013;19(7):E322\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"1057_CR9","doi-asserted-by":"crossref","unstructured":"Burnett D. Immunoglobulins in the lungs. Thorax. 1986;41(5):337\u201344.","DOI":"10.1136\/thx.41.5.337"},{"issue":"5","key":"1057_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201311-1971OC","volume":"190","author":"ST Gohy","year":"2014","unstructured":"Gohy ST, Detry BR, Lecocq M, Bouzin C, Weynand BA, Amatngalim GD, et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-beta. Am J Respir Crit Care Med. 2014;190(5):509\u201321.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1057_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1164\/rccm.201010-1629OC","volume":"184","author":"VV Polosukhin","year":"2011","unstructured":"Polosukhin VV, Cates JM, Lawson WE, Zaynagetdinov R, Milstone AP, Massion PP, et al. Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(3):317\u201327.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1057_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00428-015-1854-0","volume":"467","author":"RH Du","year":"2015","unstructured":"Du RH, Richmond BW, Blackwell TS Jr, Cates JM, Massion PP, Ware LB, et al. Secretory IgA from submucosal glands does not compensate for its airway surface deficiency in chronic obstructive pulmonary disease. Virchows Arch. 2015;467(6):657\u201365.","journal-title":"Virchows Arch"},{"issue":"6","key":"1057_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1517\/17425247.2015.999039","volume":"12","author":"R Respaud","year":"2015","unstructured":"Respaud R, Vecellio L, Diot P, Heuze-Vourc\u2019h N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12(6):1027\u201339.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"1057_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1871528111312020002","volume":"12","author":"C Kane","year":"2013","unstructured":"Kane C, O'Neil K, Conk M, Picha K. Inhalation delivery of protein therapeutics. Inflamm Allergy Drug Targets. 2013;12(2):81\u20137.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1\u20132","key":"1057_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijpharm.2013.11.042","volume":"461","author":"YB Wang","year":"2014","unstructured":"Wang YB, Watts AB, Peters JI, Williams RO 3rd. The impact of pulmonary diseases on the fate of inhaled medicines--a review. Int J Pharm. 2014;461(1\u20132):112\u201328.","journal-title":"Int J Pharm"},{"key":"1057_CR16","doi-asserted-by":"publisher","unstructured":"Dee S. Prolonged survival of a SCID patient with parainfluenza infection treated with nebulized IgG, ribavirin, and inhaled steroids. J Allergy Clin Immunol. 2012;105(Abstract 662). \n                    https:\/\/doi.org\/10.1016\/S0091-6749(00)91090-X\n                    \n                  .","DOI":"10.1016\/S0091-6749(00)91090-X"},{"issue":"4","key":"1057_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/00006454-199404000-00018","volume":"13","author":"PC Rimensberger","year":"1994","unstructured":"Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J. 1994;13(4):328\u201330.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"1057_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00006454-199603000-00007","volume":"15","author":"PC Rimensberger","year":"1996","unstructured":"Rimensberger PC, Burek-Kozlowska A, Morell A, Germann D, Eigenmann AK, Steiner F, et al. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J. 1996;15(3):209\u201316.","journal-title":"Pediatr Infect Dis J"},{"issue":"31","key":"1057_CR19","doi-asserted-by":"publisher","first-page":"21617","DOI":"10.1074\/jbc.M114.549139","volume":"289","author":"S Longet","year":"2014","unstructured":"Longet S, Vonarburg C, Lotscher M, Miescher S, Zuercher A, Corthesy B. Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen. J Biol Chem. 2014;289(31):21617\u201326.","journal-title":"J Biol Chem"},{"issue":"6","key":"1057_CR20","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1074\/jbc.M112.410811","volume":"288","author":"S Longet","year":"2013","unstructured":"Longet S, Miled S, Lotscher M, Miescher SM, Zuercher AW, Corthesy B. Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J Biol Chem. 2013;288(6):4085\u201394.","journal-title":"J Biol Chem"},{"issue":"13","key":"1057_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/08958370802207318","volume":"20","author":"DJ Alexander","year":"2008","unstructured":"Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, et al. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20(13):1179\u201389.","journal-title":"Inhal Toxicol"},{"key":"1057_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2014.10.003","volume":"93","author":"SP Hertel","year":"2015","unstructured":"Hertel SP, Winter G, Friess W. Protein stability in pulmonary drug delivery via nebulization. Adv Drug Deliv Rev. 2015;93:79\u201394.","journal-title":"Adv Drug Deliv Rev"},{"key":"1057_CR23","doi-asserted-by":"crossref","unstructured":"Rennard S. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol. 1986;60(2):532-8.","DOI":"10.1152\/jappl.1986.60.2.532"},{"issue":"2","key":"1057_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/mi.2013.41","volume":"7","author":"EN Janoff","year":"2014","unstructured":"Janoff EN, Rubins JB, Fasching C, Charboneau D, Rahkola JT, Plaut AG, et al. Pneumococcal IgA1 protease subverts specific protection by human IgA1. Mucosal Immunol. 2014;7(2):249\u201356.","journal-title":"Mucosal Immunol"},{"issue":"6","key":"1057_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","volume":"56","author":"NR Labiris","year":"2003","unstructured":"Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588\u201399.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1057_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s11095-011-0442-5","volume":"28","author":"A Maillet","year":"2011","unstructured":"Maillet A, Guilleminault L, Lemarie E, Lerondel S, Azzopardi N, Montharu J, et al. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res. 2011;28(9):2147\u201356.","journal-title":"Pharm Res"},{"issue":"7","key":"1057_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1517\/14712598.4.7.1029","volume":"4","author":"DW Grainger","year":"2004","unstructured":"Grainger DW. Controlled-release and local delivery of therapeutic antibodies. Expert Opin Biol Ther. 2004;4(7):1029\u201344.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1057_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","volume":"11","author":"BS Quon","year":"2014","unstructured":"Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11(3):425\u201334.","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"1057_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJM199409083311003","volume":"331","author":"HJ Fuchs","year":"1994","unstructured":"Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme study group. N Engl J Med. 1994;331(10):637\u201342.","journal-title":"N Engl J Med"},{"issue":"3","key":"1057_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00063030-200519030-00001","volume":"19","author":"R Suri","year":"2005","unstructured":"Suri R. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs. 2005;19(3):135\u201344.","journal-title":"BioDrugs"},{"issue":"6","key":"1057_CR31","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","volume":"125","author":"M Lucas","year":"2010","unstructured":"Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354\u201360 e4.","journal-title":"J Allergy Clin Immunol"},{"key":"1057_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1183\/09031936.01.00228801","volume":"18","author":"C Pilette","year":"2001","unstructured":"Pilette C. Lung mucosal immunity: immunoglobulin-a revisited. Eur Respir J. 2001;18:571\u201388.","journal-title":"Eur Respir J"},{"issue":"5","key":"1057_CR33","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4161\/mabs.29938","volume":"6","author":"R Respaud","year":"2014","unstructured":"Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille JF, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. mAbs. 2014;6(5):1347\u201355.","journal-title":"mAbs"},{"issue":"1\u20132","key":"1057_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijpharm.2007.02.035","volume":"339","author":"T Ghazanfari","year":"2007","unstructured":"Ghazanfari T, Elhissi AM, Ding Z, Taylor KM. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharm. 2007;339(1\u20132):103\u201311.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"1057_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","volume":"406","author":"TC Carvalho","year":"2011","unstructured":"Carvalho TC, Peters JI, Williams RO 3rd. Influence of particle size on regional lung deposition--what evidence is there? Int J Pharm. 2011;406(1\u20132):1\u201310.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"1057_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijpharm.2016.02.005","volume":"502","author":"F Buttini","year":"2016","unstructured":"Buttini F, Rossi I, Di Cuia M, Rossi A, Colombo G, Elviri L, et al. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. Int J Pharm. 2016;502(1\u20132):242\u20138.","journal-title":"Int J Pharm"},{"issue":"5","key":"1057_CR37","doi-asserted-by":"publisher","first-page":"052603","DOI":"10.1063\/1.4917181","volume":"9","author":"C Cortez-Jugo","year":"2015","unstructured":"Cortez-Jugo C, Qi A, Rajapaksa A, Friend JR, Yeo LY. Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics. 2015;9(5):052603.","journal-title":"Biomicrofluidics."},{"issue":"5","key":"1057_CR38","doi-asserted-by":"publisher","first-page":"L1002","DOI":"10.1152\/ajplung.00260.2003","volume":"286","author":"C Lombry","year":"2004","unstructured":"Lombry C, Edwards DA, Preat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol. 2004;286(5):L1002\u20138.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"1057_CR39","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.4161\/mabs.34454","volume":"6","author":"V Herve","year":"2014","unstructured":"Herve V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, et al. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. mAbs. 2014;6(6):1638\u201348.","journal-title":"mAbs"},{"issue":"1","key":"1057_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46\u201361.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1057_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clim.2009.10.003","volume":"135","author":"PL Yong","year":"2010","unstructured":"Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the primary immunodeficiency Committee of the American Academy of allergy asthma and immunology. Clin Immunol. 2010;135(2):255\u201363.","journal-title":"Clin Immunol"},{"issue":"10","key":"1057_CR42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1586\/1744666X.2015.1075396","volume":"11","author":"P Mohammadinejad","year":"2015","unstructured":"Mohammadinejad P, Ataeinia B, Kaynejad K, Zeinoddini A, Sadeghi B, Hosseini M, et al. Antibiotic resistance in patients with primary immunodeficiency disorders versus immunocompetent patients. Expert Rev Clin Immunol. 2015;11(10):1163\u201372.","journal-title":"Expert Rev Clin Immunol"},{"key":"1057_CR43","doi-asserted-by":"crossref","unstructured":"Klugman KP. Streptococcus pneumoniae respiratory tract infections. Curr Opin Infect Dis. 2001;14(2):173-9.","DOI":"10.1097\/00001432-200104000-00011"},{"key":"1057_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrmicro1871","volume":"6","author":"A Kadioglu","year":"2008","unstructured":"Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol. 2008;6:288.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"1057_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.it.2003.12.006","volume":"25","author":"A Kadioglu","year":"2004","unstructured":"Kadioglu A, Andrew PW. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 2004;25(3):143\u20139.","journal-title":"Trends Immunol"},{"key":"1057_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1128\/9781555815820.ch15","volume-title":"Pneumococcal Vaccines The impact of conjugate vaccine","author":"MH Nahm","year":"2008","unstructured":"Nahm MH, Romero-Steiner S. Functional assays for pneumococcal antibody. In: Siber GR, Klugman KP, Makela PH, editors. Pneumococcal Vaccines The impact of conjugate vaccine. Washington, DC: ASM Press; 2008. p. 213\u201326."},{"issue":"1","key":"1057_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/mi.2014.55","volume":"8","author":"AM Roche","year":"2015","unstructured":"Roche AM, Richard AL, Rahkola JT, Janoff EN, Weiser JN. Antibody blocks acquisition of bacterial colonization through agglutination. Mucosal Immunol. 2015;8(1):176\u201385.","journal-title":"Mucosal Immunol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1057-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T19:29:50Z","timestamp":1590002990000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1057-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal welfareThe UK Home Office controls scientific procedures on animals in the UK and does so by issue of licences under the Animals (Scientific Procedures) Act 1986. The regulations conform to EU Directive 2010\/63\/EU and achieve the standard of care required by the US Department of Health and Human Services\u2019 Guide for the Care and Use of Laboratory.The CSL\/Zoetis Animal Ethics Committee, the Albany Medical College IACUC and the University of Melbourne Animal Ethics Committee approved all mouse related procedures and protocols.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CV, KS and UB declare the submission of patent WO2015\/150510, pending to CSL Behring AG, PARI Pharma GmBH, Hanover Medical School (University of Hannover). Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"99"}}